Gossamer Bio Inc.
(NASDAQ:GOSS) stock is trading higher on Monday as the company is preparing to submit a New Drug Application (NDA) for its lead candidate, seralutinib, in September 2026 following a pre-NDA Type B meeting with the U.S.
Food and Drug Administration (FDA).
The clinical-stage biopharmaceutical company announced the timeline alongside major corporate updates, including regaining full global commercial rights to the candidate and completing significant balance sheet restructuring.
Read Also: AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial FDA Alignment And Regulatory Roadmap During the mid-June 2026 meeting, the FDA characterized the treatment effect and statistical significance observed in the Phase 3 PROSERA study as review issues rather than filing hurdles.
